ArticleFrontiers in immunology2021

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.

Hans de Graaf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.